TR-PCI: Upper Extremity Function Post Transradial PCI

Original Title: Upper extremity function post-transradial (TR)-PCI: interim results.
Presenter: Eva Zwaan.

 

The use of transradial access has increased in the clinical practice thanks to the reduction of vascular and bleeding complications in addition to the shorter time of hospitalization.

 

The aim of this study was to assess prevalence, magnitude and mechanisms responsible for the upper extremity dysfunction by transradial PCI (TR PCI). It was an observational, prospective, multicenter study with functional assessment of both upper extremities by Doppler to the radial artery, hand and forearm volumetric and palm pressure sensitivity assessment at 24 hrs., 2 weeks, 1 month and 6 months after procedure. Primary end point was positive dysfunction score validated by a surgeon.

 

74.9% of patients presented some dysfunction of the upper extremity at 2 weeks after procedure vs. the contralateral upper extremity.
The most frequent cause of dysfunction were sensitivity reduction, increase of arm volume and elbow strength reduction.
9.8% of patients presented radial artery occlusion.

 

Conclusion
According to this work, there is high prevalence of upper extremity dysfunction where transradial access was used 2 weeks after procedure. We should wait to complete follow up to determine whether there are more long-lasting complications.

 

More articles by this author

VELETI II: PCI to Intermediate coronary SVG lesions with DES

Original Title: Sealing intermediate non-obstructive coronary SVG lesions with DES as a new approach to maintaining vein graft patency and reducing cardiac events: the...

TriGuard: NeuroProtection Device during TAVI

Original Title: A Patient Level Pooled Analysis of NeuroProtection with the TriGuard Embolic DEFLECTion Device Compared to Unprotected Transcatheter Aortic Valve Replacement. Presenter: Alexandra Lansky   This...

MATRIX: Transradial vs. Femoral Access in Non-ST Elevation AMI

Original Title: Radial versus femoral access in patients with acute coronary syndromes with or without ST-segment elevation. Presenter: Bernardo Cortese.   The MATRIX study showed that the...

FRONTIER II: One Year Outcomes of the New Vascular Closure Device

Original Title: 12-month results of a novel large access closure device: insights from the FRONTIER II Study. Presenter: Arne Schwindt   The FRONTIER II trial assessed the...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....